Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm).
Jonathan A. Ledermann
Other Remuneration - AstraZeneca
Philipp Harter
Consultant or Advisory Role - AstraZeneca
Research Funding - AstraZeneca
Charlie Gourley
Consultant or Advisory Role - Boehringer Ingelheim; Chugai Pharma; GlaxoSmithKline; Merck; Roche
Honoraria - Boehringer Ingelheim; Chugai Pharma; GlaxoSmithKline; Merck; Roche
Research Funding - AstraZeneca
Other Remuneration - Boehringer Ingelheim; Merck; PharmaMar; Roche
Michael Friedlander
No relevant relationships to disclose
Ignace Vergote
No relevant relationships to disclose
Gordon J. S. Rustin
Consultant or Advisory Role - AstraZeneca
Clare L. Scott
Honoraria - Sanofi
Other Remuneration - AstraZeneca
Werner Meier
No relevant relationships to disclose
Ronnie Shapira-Frommer
No relevant relationships to disclose
Tamar Safra
No relevant relationships to disclose
Daniela Matei
No relevant relationships to disclose
Anitra Fielding
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Euan Macpherson
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Brian Dougherty
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Juliane M. Jürgensmeier
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Maria Orr
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Ursula Matulonis
Research Funding - AstraZeneca